AstraZeneca PLC (NASDAQ:AZN) Holdings Cut by GenTrust LLC

GenTrust LLC cut its stake in shares of AstraZeneca PLC (NASDAQ:AZN) by 38.5% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 4,451 shares of the company’s stock after selling 2,785 shares during the quarter. GenTrust LLC’s holdings in AstraZeneca were worth $347,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in the stock. Clal Insurance Enterprises Holdings Ltd acquired a new stake in shares of AstraZeneca in the 3rd quarter worth about $234,000. Nwam LLC acquired a new stake in shares of AstraZeneca in the third quarter valued at approximately $627,000. Meridian Wealth Management LLC bought a new stake in shares of AstraZeneca during the third quarter valued at approximately $1,005,000. Biltmore Family Office LLC acquired a new position in shares of AstraZeneca during the third quarter worth approximately $230,000. Finally, Charles Schwab Investment Management Inc. grew its holdings in AstraZeneca by 0.5% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,784,235 shares of the company’s stock worth $139,010,000 after buying an additional 8,830 shares in the last quarter. 20.35% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several analysts have weighed in on the company. UBS Group raised AstraZeneca from a “sell” rating to a “neutral” rating in a research note on Wednesday. TD Cowen lifted their price objective on shares of AstraZeneca from $90.00 to $95.00 and gave the company a “buy” rating in a research note on Monday, August 12th. Erste Group Bank upgraded shares of AstraZeneca from a “hold” rating to a “buy” rating in a research report on Wednesday, September 11th. Finally, Deutsche Bank Aktiengesellschaft upgraded shares of AstraZeneca from a “sell” rating to a “hold” rating in a research report on Wednesday, November 6th. Three analysts have rated the stock with a hold rating, seven have assigned a buy rating and two have given a strong buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $89.75.

AstraZeneca Stock Up 2.1 %

NASDAQ AZN opened at $65.63 on Friday. The company has a market capitalization of $203.49 billion, a P/E ratio of 31.40, a PEG ratio of 1.18 and a beta of 0.47. AstraZeneca PLC has a 12 month low of $60.47 and a 12 month high of $87.68. The company has a debt-to-equity ratio of 0.71, a current ratio of 0.93 and a quick ratio of 0.71. The company’s 50 day simple moving average is $73.44 and its 200 day simple moving average is $77.79.

AstraZeneca (NASDAQ:AZN) last announced its quarterly earnings data on Tuesday, November 12th. The company reported $1.04 EPS for the quarter, beating analysts’ consensus estimates of $1.01 by $0.03. The company had revenue of $13.57 billion during the quarter, compared to the consensus estimate of $13.08 billion. AstraZeneca had a return on equity of 30.01% and a net margin of 12.68%. The company’s quarterly revenue was up 18.0% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.87 EPS. Equities research analysts expect that AstraZeneca PLC will post 4.1 earnings per share for the current fiscal year.

AstraZeneca Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.